Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY-NC-ND 4.0JACC Case Reports

Cardiovascular Outcomes With Sodium-Glucose Cotransporter 2 Inhibitors in Ethnically Diverse Patients With Heart Failure

  • Sun Yong Lee1,2
  • Tiffany Vu2,3
  • Jessica Song3
  • Mohsen Saadat2
  • Taylor Thai3
  • Rajkumar J. Sevak3
  • Elisa Nguyen3
  • Harnoor Gill3
  • Cesfe Banola2
  • Syung Min Jung2
  1. 1St Joseph's Medical Center, Cardiovascular Disease Fellowship, Department of Medicine/Division of Cardiology, Stockton, California, USA
  2. 2San Joaquin General Hospital, Internal Medicine Department, French Camp, California, USA
  3. 3Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California, USA
Read full textPDFDOICite

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to decrease heart failure hospitalizations (HFHs) and cardiovascular (CV) death; however, Hispanic/Latino patients and methamphetamine (MA) users have been under-represented.

Project Rationale: The purpose of this retrospective study was to assess CV outcomes in the Central Valley region of California within 12 months of starting a SGLT2i.

Project Summary: Overall, 413 patients were included, with non-White patients and MA users accounting for 72% and 27% of the population, respectively. The composite CV outcome occurred in 86 of 413 patients (20.8%), 22% of Whites and 19%-27% of non-Whites. Significantly reduced HFH rates were observed in the overall population and subgroups after 1 year of starting SGLT2i. Reduced left ventricular ejection fraction, prior HFH, and MA use predicted CV outcomes, though the retrospective nature of this analysis limits causal inference.

Take-Home Message: MA use, prior HFH, and reduced left ventricular ejection fraction predicted CV outcomes, irrespective of ethnicity.

Related

  1. Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
    Frances Perry, Silvia J. Leon, Kate Polecina +10
    Diabetes, Obesity & MetabolismPeer-reviewedCC BY-NC 4.0Full textEndocrinology & metabolismPMC
  2. Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
    Lama Alfehaid, Ahmed S. Alanazi, Mansour Alomran +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  3. Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Decompensated Heart Failure: Efficacy, Safety, and Implementation in Stabilized Patients
    Alfredo Mauriello, Adriana Correra, Anna Chiara Maratea +11
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network
    Leandra Serio, Michele Rossi, Amir Askarinejad +6
    Diabetes, Obesity & MetabolismPeer-reviewedCC BY 4.0Full textHuman geneticsPMC
  5. Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes
    Ibrahim Mortada, Krishna Paul, James Rice +7
    Diabetes & Vascular Disease ResearchPeer-reviewedCC BY-NC 4.0Full textEndocrinology & metabolismPMC

Cite

BibTeXRIS
BibTeX
@article{lee2026cardiovascular,
  title = {{Cardiovascular Outcomes With Sodium-Glucose Cotransporter 2 Inhibitors in Ethnically Diverse Patients With Heart Failure}},
  author = {Sun Yong Lee and Tiffany Vu and Jessica Song and Mohsen Saadat and Taylor Thai and Rajkumar J. Sevak and Elisa Nguyen and Harnoor Gill and Cesfe Banola and Syung Min Jung},
  journal = {JACC Case Reports},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jaccas.2026.109454},
  url = {https://doi.org/10.1016/j.jaccas.2026.109454},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Cardiovascular Outcomes With Sodium-Glucose Cotransporter 2 Inhibitors in Ethnically Diverse Patients With Heart Failure
AU  - Sun Yong Lee
AU  - Tiffany Vu
AU  - Jessica Song
AU  - Mohsen Saadat
AU  - Taylor Thai
AU  - Rajkumar J. Sevak
AU  - Elisa Nguyen
AU  - Harnoor Gill
AU  - Cesfe Banola
AU  - Syung Min Jung
PY  - 2026
DA  - 2026/09/16
JO  - JACC Case Reports
DO  - 10.1016/j.jaccas.2026.109454
UR  - https://doi.org/10.1016/j.jaccas.2026.109454
AB  - Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to decrease heart failure hospitalizations (HFHs) and cardiovascular (CV) death; however, Hispanic/Latino patients and methamphetamine (MA) users have been under-represented.  Project Rationale: The purpose of this retrospective study was to assess CV outcomes in the Central Valley region of California within 12 months of starting a SGLT2i.  Project Summary: Overall, 413 patients were included, with non-White patients and MA users accounting for 72% and 27% of the population, respectively. The composite CV outcome occurred in 86 of 413 patients (20.8%), 22% of Whites and 19%-27% of non-Whites. Significantly reduced HFH rates were observed in the overall population and subgroups after 1 year of starting SGLT2i. Reduced left ventricular ejection fraction, prior HFH, and MA use predicted CV outcomes, though the retrospective nature of this analysis limits causal inference.  Take-Home Message: MA use, prior HFH, and reduced left ventricular ejection fraction predicted CV outcomes, irrespective of ethnicity.
SN  - 2666-0849
ER  -